topic

195 Avelumab internalization and lysosomal degradation by circulating immune cells in human is mediated by both Fc gamma Receptor (FcgR) and PD-L1 binding
Hulin Jin, Vittorio D’Urso, Berend Neuteboom, Sean McKenna, Rene Schweickhardt, Alec Gross, Yves Fomekong Nanfack, Lars Toleikis, Markus Fluck, Juergen Scheuenpflug, Ti Cai

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A115; DOI: 10.1136/jitc-2020-SITC2020.0195
198 Combination intratumoral treatment with INTASYL™ self-delivering RNAi targeting TIGIT and PD-1/PD-L1 improves tumor control compared to monotherapy in a CT26 model of murine colorectal cancer
Benjamin Cuiffo, Melissa Maxwell, Dingxue Yan, Andrej Jedinak, James Cardia, Simon Fricker

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A116-A117; DOI: 10.1136/jitc-2020-SITC2020.0198
197 Survival outcomes and toxicity among patients treated with concomitant radiotherapy and immunotherapy for advanced melanoma: two faces of the abscopal effect?
Nikolaos Andreatos, Joanna Roopkumar, Alok Khorana, Neil Woody, Brian Gastman, Pauline Funchain

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A116; DOI: 10.1136/jitc-2020-SITC2020.0197
204 The role of immune checkpoint inhibitor as a single agent or combination therapy in advanced thyroid cancer
Ju Young Lee, Inae Park, Myungwoo Nam, Christmann Low, Eugene Kim, Hansol Choi, Elena Vagia, Chan Mi Jung, Young Kwang Chae

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A119-A121; DOI: 10.1136/jitc-2020-SITC2020.0204
23 Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA4 rescue in patients with mismatch repair deficient metastatic colorectal cancer
Pashtoon Kasi, Carlos Chan

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A12-A13; DOI: 10.1136/jitc-2020-SITC2020.0023
205 PD-1/PD-L1/CTLA-4 inhibitor therapy following progression on a different PD-1/PD-L1 inhibitor: a case series
Suresh Mukkamala, Karine Tawagi, Marc Matrana

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A121; DOI: 10.1136/jitc-2020-SITC2020.0205
208 E7777 (denileukin diftitox) enhances anti-tumor activity and significantly extends survival benefit of anti-PD-1 in syngeneic solid tumor models
Mary Woodall-Jappe, A Raghav Chari, Anil Namboodiripad, Chandrasekhar Goda

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A122-A123; DOI: 10.1136/jitc-2020-SITC2020.0208
211 Targeting BTN2A1 modulates anti-tumor activity of Vg9Vd2 T cells
Carla Cano, Aude de Gassart, Christine Pasero, Melanie Gabriac, Marie Fullana, Emilie Granarolo, HOET Rene, Caroline Imbert, Laurent Gorvel, Antoine Briantais, Anne-Charlotte Le Floch, Daniel Olive

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A126-A127; DOI: 10.1136/jitc-2020-SITC2020.0211
212 CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and synergizing with tumor-targeted antibodies
Vanessa Gauttier, Marion Drouin, Sabrina Pengam, Javier Saenz, Bérangère Evrard, Caroline Mary, Géraldine Teppaz, Ariane Desselle, Virginie Thépénier, Emmanuelle Wilhelm, Elise Chiffoleau, Nicolas Poirier

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A127; DOI: 10.1136/jitc-2020-SITC2020.0212
215 AO-176, a highly differentiated clinical stage anti-CD47 antibody, preferentially binds tumor versus normal cell CD47 when complexed to β1 integrin
Robyn Puro, Prabir Chakraborty, John Richards, Ronald Hiebsch, Michael Donio, W Casey Wilson, Benjamin Capoccia, Carrie Brachmann, Vicki Sung, Arun Kashyap, Daniel Pereira

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A128-A129; DOI: 10.1136/jitc-2020-SITC2020.0215

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages